By Editor , 4 November 2026
Bio-Techne Ties $0.08 Dividend to Merck KGaA Deal Timing

MINNEAPOLIS – – November 03, 2026 -- Bio-Techne Corporation (NASDAQ: TECH) will pay a quarterly dividend of $0.08 per share only if its pending transaction with Merck KGaA, Darmstadt, Germany has not closed by the close of business on November 13, 2026.

By Editor , 4 November 2026
TXP Medical: Japan's EMR Data Market to Reach ¥25 Billion by 2035

TOKYO – November 03, 2026 -- Japan's market for EMR-derived healthcare data is projected to grow from about ¥3.9 billion in 2025 to about ¥25 billion in 2035, according to a whitepaper from TXP Medical Co., Ltd. The report, "The State of Japanese Real-World Evidence," targets pharmaceutical Medical Affairs departments. It is the first publication from the company's relaunched "Medical Data Lab" media unit.

By Editor , 4 November 2026
ACT for ALS Reauthorized: Up to $500M for Research and Access

WASHINGTON – November 03, 2026 -- The President has signed the ACT for ALS reauthorization bill into law, extending the program for five years and committing up to an additional $500 million to ALS research infrastructure and investigational treatment access, according to patient advocacy group I AM ALS.

By Editor , 4 November 2026
ACT for ALS Reauthorized Through 2031 After Presidential Signing

Arlington, Virginia – November 03, 2026 -- The President has signed the bipartisan ACT for ALS Act into law, extending the research and treatment access programs created under the original 2021 legislation through 2031, according to the ALS Association.

By Editor , 4 November 2026
Cepheid wins FDA clearance for 61-minute hemorrhagic fever panel

SUNNYVALE – – November 03, 2026 -- Cepheid, a Danaher operating company, has received U.S. Food and Drug Administration clearance for the Xpert Hemorrhagic Fever Panel, a multiplex PCR test that detects four hemorrhagic fever virus groups from a single sample in approximately 61 minutes.

By Editor , 4 November 2026
NCI Awards $10M to Montefiore Einstein Team for Breast Cancer Relapse Study

Bronx, N.Y. – – November 03, 2026 -- The National Cancer Institute (NCI) has awarded a five-year, $10 million grant to a multi-institutional team led by Julio A. Aguirre-Ghiso, Ph.D., of Montefiore Einstein Comprehensive Cancer Center (MECCC). The money will fund research into the biological processes behind breast cancer relapse and into ways to predict and prevent recurrence.

By Editor , 4 November 2026
Signant Health Launches SignalSpace to Unify Clinical Trial Data

Philadelphia – November 03, 2026 -- Signant Health has launched SignalSpace, a connected environment that combines its applications, study activity, support, workflows, data and AI-guided intelligence in one secure destination for sites, sponsors and CROs. SignalSpace comes standard with Signant solutions.

By Editor , 4 November 2026
Allergan Aesthetics Brings Nine Abstracts, GLP-1 Data to ASDS 2026

Irvine, California – November 03, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, including new data from two Phase 4 studies on aesthetic treatment in patients taking GLP-1-related medications for weight management.